Loss of p53 expression correlates with metastatic phenotype and transcriptional profile in a new mouse model of head and neck cancer

Molecular Cancer Research

Volumn 5, Issue 4, 2007, Pages 351-362

  Ku, Tony K S ^a   Nguyen, Dan C ^a   Karaman, Mazen ^b   Gill, Parkash ^b,c   Hacia, Joseph G ^b   Crowe, David L ^a,c,d  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN P53;

ALLELE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CARCINOGENESIS; CERVICAL LYMPH NODE; CONTROLLED STUDY; FEMALE; HEAD AND NECK CANCER; HETEROZYGOSITY; HISTOPATHOLOGY; MALE; METASTASIS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; TUMOR DIFFERENTIATION; UNINDEXED SEQUENCE;

ANIMALS; CARCINOMA, SQUAMOUS CELL; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HEAD AND NECK NEOPLASMS; LYMPH NODES; MICE; MICE, KNOCKOUT; MOLECULAR SEQUENCE DATA; NEOPLASM METASTASIS; NEOPLASM STAGING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHENOTYPE; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53;

ANIMALIA; MUS; RODENTIA;

EID: 34248192422     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-06-0238     Document Type: Article

References (61)

1. Moore SR, Johnson NW, Pierce AM, et al. The epidemiology of mouth cancer: a review of global incidence. Oral Dis 2000;6:65-74.
2. Goldberg HI, Lockwood SA, Wyatt SW, et al. Trends and differentials in mortality from cancers of the oral cavity and pharynx in the United States, 1973-1987. Cancer 1994;74:565-72.
3. Grandis JR, Pietenpol JA, Greenberger JS, et al. Head and neck cancer: meeting summary and research opportunities. Cancer Res 2004;64:8126-9.
4. Crowe DL, Hacia JG, Hsieh CL, et al. Molecular pathology of head and neck cancer. Histol Histopathol 2002;17:909-14.
5. Schwarz JL, Shklar G. Verification in syngeneic hamsters of in vitro transformation of hamster oral mucosa by 7,12-dimethylbenz(a) anfhracene. Oral Oncol 1997;33:431-8.
6. Rheinwald JG, Beckett MA. Tumorigenic keratinocyte lines requiring anchorage and fibroblast support cultures from human squamous cell carcinomas. Cancer Res 1981;41:1657-63.
7. Kawashiri S, Kumagai S, Kojima K, et al. Reproduction of occult metastasis of head and neck cancer in nude mice. Clin Exp Metastasis 1999;17:277-82.
8. Simon C, Hicks MJ, Nemechek AJ, et al. PD98059, an inhibitor of ERK1 activation, attenuates the in vivo invasiveness of head and neck squamous cell carcinoma. Br J Cancer 1999;80:1412-9.
9. Caulin C, Nguyen T, Longley MA, et al. Inducible activation of oncogenic K-ras results in tumor formation in the oral cavity. Cancer Res 2004;64:5054-8.
10. Vitale-Cross L, Amornphimoltham P, Fisher G, et al. Conditional expression of K-ras in an epithelial compartment that includes stem cells is sufficient to promote squamous cell carcinogenesis. Cancer Res 2004;64:8804-7.
11. Saranath D, Chang SE, Bhoite LT, et al. High frequency mutation in codons 12 and 61 of H-ras oncogene in chewing tobacco related human oral carcinoma in India. Br J Cancer 1991;63:573-8.
12. Munirajan AK, Mohanprasad BK, Shanmugam G, et al. Detection of a rare point mutation at codon 59 and relatively high incidence of H-ras mutation in Indian oral cancer. Int J Oncol 1998;13:971-4.
13. Hollstein M, Rice K, Greenblatt MS, et al. Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res 1994;22:3551-5.
14. Kashiwazaki H, Tonoki H, Tada M, et al. High frequency of p53 mutations in human oral epithelial dysplasia and primary squamous cell carcinoma detected by yeast functional assay. Oncogene 1997;15:2667-74.
15. Qin GZ, Park JY, Chen SY, et al. A high prevalence of p53 mutations in premalignant oral erythroplakia. Int J Cancer 1999;80:345-8.
16. Gasco M, Crook T. The p53 network in head and neck cancer. Oral Oncol 2003;39:222-31.
17. Oren M. Regulation of the p53 tumor suppressor protein. J Biol Chem 1999; 274:36031-4.
18. Zauberman A, Lubp A, Oren M. Identification of p53 target genes through immune selection of genomic DNA. Oncogene 1995;10:2361-6.
19. Donehower LA, Harvey M, Slagle BL, et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumors. Nature 1992;356: 215-21.
20. Strati K, Pitot HC, Lambert PF. Identification of biomarkers that distinguish human papillomavirus (HPV)-positive versus HPV negative head and neck cancers in a mouse model. Proc Natl Acad Sci U S A 2006;103:14152-7.
21. Nguyen DC, Parsa B, Close A, et al. Overexpression of cell cycle regulatory proteins correlates with advanced tumor stage in head and neck squamous cell carcinomas. Int J Oncol 2003;22:1285-90.
22. Hitt R, Ciruelos E, Amador ML, et al. Prognostic value of the epidermal growth factor receptor (EGFR) and p53 in advanced head and neck squamous cello carcinoma patients treated with induction chemotherapy. Eur J Cancer 2005; 41:453-60.
23. Uchida D, Kawamata H, Omotehara F, et al. Role of HGF/c-met system in invasion and metastasis of oral squamous cell carcinoma cells in vitro and its clinical significance. Int J Cancer 2001;93:489-96.
24. Tsang DK, Crowe DL. The mitogen activated protein kinase pathway is required for proliferation but not invasion of human squamous cell carcinoma lines. Int J Oncol 1999;15:519-23.
25. Field JK. Oncogenes and tumor suppressor genes in squamous cell carcinoma of the head and neck. Eur J Cancer B Oral Oncol 1992;28:67-76.
26. Namazie A, Alavi S, Olopade OI, et al. Cyclin D1 amplification and p16(MTS1/CDK4I) deletion correlate with poor prognosis in head and neck tumors. Laryngoscope 2002;112:472-81.
27. Shin DM, Charuruks N, Lippman SM, et al. p53 protein accumulation and genomic instability in head and neck multistep tumorigenesis. Cancer Epidemiol Biomarkers Prev 2001;10:603-9.
28. Takes RP, Baatenburg de Jong RJ, Wijffels K, et al. Expression of genetic markers in lymph node metastases compared with their primary tumors in head and neck cancer. J Pathol 2001;194:298-302.
29. Bradford CR, Zhu S, Ogawa H, et al. p53 mutation correlates with cisplatin sensitivity in head and neck squamous cell carcinoma lines. Head Neck 2003;25: 654-61.
30. Hitt R, Ciruelos E, Amador ML, et al. Prognostic value of the epidermal growth factor receptor (EGFR) and p53 in advanced head and neck squamous cell carcinoma patients treated with induction chemotherapy. Eur J Cancer 2005;41: 453-60.
31. Crowe DL, Sinha UK. p53 apoptotic response to DNA damage dependent on bcl2 but not bax in head and neck squamous cell carcinoma lines. Head Neck 2006;28:15-23.
32. Dolivet G, Merlin JL, Barberi-Heyob M, et al. In vivo growth inhibitory effect of iterative wild type p53 gene transfer in human head and neck carcinoma xenografts using glucosylated polyethylenimine nonviral vector. Cancer Gene Ther 2002;9:708-14.
33. Friedlander PL. Genomic instability in head and neck cancer patients. Head Neck 2001;23:683-91.
34. Wang XJ. Role of TGFβ signaling in skin carcinogenesis. Microsc Res Tech 2001;52:420-9.
35. Grande JP. Role of transforming growth factor β in tissue injury and repair. Proc Soc Exp Biol Med 1997;214:27-40.
36. Bakin AV, Rinehart C, Tomlinson AK, et al. p38 mitogen activated protein kinase is required for TGFβ mediated fibroblastic transdifferentiation and cell migration. J Cell Sci 2002;115:3193-206.
37. Muraoka-Cook RS, Dumont N, Arteaga CL. Dual role of transforming growth factor β in mammary tumorigenesis and metastatic progression. Clin Cancer Res 2005;11:937-43.
38. Nobuhara Y, Onoda N, Yamashita Y, et al. Efficacy of epidermal growth factor receptor targeted molecular therapy in anaplastic thyroid cancer cell lines. Br J Cancer 2005;92:1110-6.
39. Wrobel G, Roerig P, Kokocinski F, et al. Microarray based gene expression profiling of benign, atypical, and anaplastic meningiomas identifies novel genes associated with meningioma progression. Int J Cancer 2005;114:249-56.
40. Ha, v-fos, or human transforming growth factor a. Cancer Res 1996;56: 4413-23.
41. Johnson AC, Murphy BA, Matelis CM, et al. Activator protein 1 mediates induced but not basal epidermal growth factor receptor gene expression. Mol Med 2000;6:17-27.
42. Deb D, Scian M, Roth KE, et al. Hetero-oligomerization does not compromise gain of function of tumor derived p53 mutants. Oncogene 2002; 21:176-89.
43. Akerman GS, Tolleson WH, Brown KL, et al. Human papillomavirus type 16 E6 and E7 cooperate to increase epidermal growth factor receptor (EGFR) mRNA levels, overcoming mechanisms by which excessive EGFR signaling shortens the lifespan of normal human keratinocytes. Cancer Res 2001;61: 3837-43.
44. Lebel M, Cardiff RD, Leder P. Tumorigenic effect of nonfunctional p53 or p21 in mice mutant in the Werner syndrome helicase. Cancer Res 2001;61: 1816-9.
45. Yamabe Y, Shimamoto A, Goto M, et al. Sp1 mediated transcription of the Werner helicase gene is modulated by Rb and p53. Mol Cell Biol 1998;18: 6191-200.
46. Kemp CJ, Donehower LA, Bradley A, et al. Reduction of p53 gene dosage does not increase initiation or promotion but enhances malignant progression of chemically induced skin tumors. Cell 1993;74:813-22.
47. Ajioka I, Akaike T, Watanabe Y. Ethanolamine is a co-mitogenic factor for proliferation of primary hepatocytes. J Cell Biochem 2002;84:249-63.
48. Shiga H, Heath EI, Rasmussen AA, et al. Prognostic value of p53, glutathione S-transferase π, and thymidylate synthase for neoadjuvant cisplatin based chemotherapy in head and neck cancer. Clin Cancer Res 1999;5:4097-104.
49. Evans AJ, Henner WD, Eilers KM, et al. Polymorphisms of GSTT1 and related genes in head and neck cancer risk. Head Neck 2004;26:63-70.
50. Pan Y, Bi F, Liu N, et al. Expression of seven main Rho family members in gastric carcinoma. Biochem Biophys Res Commun 2004;315:686-91.
51. Van Oijen MG, Rijksen G, ten Broek FW, et al. Overexpression of c-src in areas of hyperproliferation in head and neck cancer, premalignant lesions, and benign mucosal disorders. J Oral Pathol Med 1998;27:147-52.
52. Zhang Q, Thomas SM, Xi S, et al. SRC family kinases mediate epidermal growth factor receptor ligand cleavage, proliferation, and invasion of head and neck cancer cells. Cancer Res 2004;64:6166-73.
53. Leong PL, Xi S, Drenning SD, et al. Differential function of STAT5 isoforms in head and neck cancer growth control. Oncogene 2002;21:2846-53.
54. Xi S, Zhang Q, Gooding WE, et al. Constitutive activation of Stat5b contributes to carcinogenesis in vivo. Cancer Res 2003;63:6763-71.
55. Stella MC, Trusolino L, Pennacchietti S, et al. Negative feedback regulation of met dependent invasive growth by Notch. Mol Cell Biol 2005;25:3982-96.
56. Matsuo K, Kobayashi I, Tsukuba T, et al. Immunohistochemical localization of cathepsins D and E in human gastric cancer: a possible correlation with local invasive and metastatic activities of carcinoma cells. Hum Pathol 1996;27:184-90.
57. 6-Fyn signaling promotes oral cancer progression. J Biol Chem 2003;278:41646-53.
58. Huguet EL, McMahon JA, McMahon AP, et al. Differential expression of human Wnt genes 2, 3, 4, and 7B in human breast cell lines and normal and disease states of human breast tissue. Cancer Res 1994;54:2615-21.
59. Verras M, Brown J, Li X, et al. Wnt3a growth factor induces androgen receptor mediated transcription and enhances cell growth in human prostate cancer cells. Cancer Res 2004;64:8860-6.
60. Bikle DD. Vitamin D and skin cancer. J Nutr 2004;134:3472-8.
61. Hu L, Crowe DL, Rheinwald JG, Chambon P, Gudas, LJ. Abnormal expression of retinoic acid receptors and keratin 19 by human oral and epidermal squamous cell carcinoma lines. Cancer Res 1991;51:3972-81.